|
Administration
Should be taken with food.
|
|
Contraindications
Hypersensitivity. Optic and retrobulbar neuritis. Inability to report visual disturbances (e.g. unconscious).
|
|
Special Precautions
Patient with ocular disease (e.g. ocular inflammatory conditions, cataracts, diabetic retinopathy). Renal impairment. Children. Pregnancy and lactation. Patient Counselling This drug may cause visual disturbances, if affected, do not drive or operate machinery. Monitoring Parameters Determine at baseline and monitor (monthly) visual and colour discrimination test results. Monitor LFT and renal function (at baseline and during therapy); other signs and symptoms of visual disturbances. Perform haematopoietic tests.
|
|
Adverse Reactions
Significant: Optic neuritis, visual disturbances (e.g. colour blindness and irreversible blindness).
Blood and lymphatic system disorders: Thrombocytopenia, eosinophilia, leucopenia, neutropenia.
Gastrointestinal disorders: Nausea, vomiting, abdominal pain, gastrointestinal upset.
General disorders and administration site conditions: Malaise, fever.
Hepatobiliary disorders: Jaundice.
Immune system disorders: Hypersensitivity reactions, erythema multiforme.
Investigations: Hyperuricaemia.
Metabolism and nutrition disorders: Anorexia.
Musculoskeletal and connective tissue disorders: Acute gout.
Nervous system disorders: Headache, dizziness, peripheral neuropathy.
Psychiatric disorders: Confusion, disorientation, hallucinations.
Respiratory, thoracic and mediastinal disorders: Pulmonary infiltrates.
Skin and subcutaneous tissue disorders: Dermatitis, erythema multiforme, pruritus.
Potentially Fatal: Hepatotoxicity. |
|
Drug Interactions
Decreased exposure with Al hydroxide.
|
|
CIMS Class
|
|
ATC Classification
J04AK02 - ethambutol ; Belongs to the class of other drugs used in the systemic treatment of tuberculosis.
|
Sign Out
